[
    [
        {
            "time": "2019-03-20",
            "original_text": "After Hours Most Active for Mar 20, 2019: NLY, XOG, GE, MCHI, ELAN, T, QQQ, MU, NWL, AMD, PFE, DIS",
            "features": {
                "keywords": [
                    "Most Active",
                    "NLY",
                    "XOG",
                    "GE",
                    "MCHI",
                    "ELAN",
                    "T",
                    "QQQ",
                    "MU",
                    "NWL",
                    "AMD",
                    "PFE",
                    "DIS"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "finance",
                    "technology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 10,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-03-20",
            "original_text": "Invest in Americaâ€™s Rising Healthcare Costs With These Stocks",
            "features": {
                "keywords": [
                    "Invest",
                    "America",
                    "Healthcare Costs",
                    "Stocks"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-20",
            "original_text": "Pfizer buys stake in French gene therapy firm Vivet",
            "features": {
                "keywords": [
                    "Pfizer",
                    "buys",
                    "stake",
                    "French",
                    "gene therapy",
                    "Vivet"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-20",
            "original_text": "Glaxo Presents Encouraging Data on Endometrial Cancer Drug",
            "features": {
                "keywords": [
                    "Glaxo",
                    "Encouraging Data",
                    "Endometrial Cancer",
                    "Drug"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-20",
            "original_text": "Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan",
            "features": {
                "keywords": [
                    "Conatus",
                    "CNAT",
                    "Developing",
                    "NASH",
                    "Emricasan"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-20",
            "original_text": "Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Merck KGaA",
                    "End",
                    "Bavencio",
                    "Talzenna",
                    "Ovarian Cancer",
                    "Study"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-20",
            "original_text": "Pfizer Acquires Gene Therapy Portfolio in Deal that Could Total $636 Million",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Acquires",
                    "Gene Therapy",
                    "Portfolio",
                    "$636 Million"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-20",
            "original_text": "Pfizer Adds to Big Pharma's Gene-Therapy Deal Streak",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Adds",
                    "Big Pharma",
                    "Gene-Therapy",
                    "Deal Streak"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pfizer Adds to Big Pharma's Gene-Therapy Deal Streak",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-20",
            "original_text": "The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company",
            "features": {
                "keywords": [
                    "Daily Biotech Pulse",
                    "FDA",
                    "Sage",
                    "Postpartum Depression",
                    "Drug",
                    "Pfizer",
                    "Invests",
                    "Gene Therapy",
                    "Company"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-20",
            "original_text": "Pfizer acquires option to buy Vivet Therapeutics for equivalent of $635.8 million",
            "features": {
                "keywords": [
                    "Pfizer",
                    "acquires",
                    "option",
                    "buy",
                    "Vivet Therapeutics",
                    "$635.8 million"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-20",
            "original_text": "Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Secures",
                    "Exclusive Option",
                    "Acquire",
                    "Gene Therapy",
                    "Vivet Therapeutics"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-20",
            "original_text": "5 High-Quality, High-Yielding Stocks",
            "features": {
                "keywords": [
                    "High-Quality",
                    "High-Yielding",
                    "Stocks"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-03-20",
            "original_text": "Stocks - FedEx, Google Fall in Pre-market; General Mills Jumps",
            "features": {
                "keywords": [
                    "Stocks",
                    "FedEx",
                    "Google",
                    "Fall",
                    "Pre-market",
                    "General Mills",
                    "Jumps"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "transportation",
                    "technology",
                    "consumer goods"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-20",
            "original_text": "Pfizer (PFE) Gains As Market Dips: What You Should Know",
            "features": {
                "keywords": [
                    "Pfizer",
                    "PFE",
                    "Gains",
                    "Market Dips"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]